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Simple Summary: In this study, the application of capillary electrophoresis mass spectrometry
enabled identification of 31 urinary peptides significantly associated with hepatocellular carcinoma
diagnosis and prognosis. Further assessment of these peptides lead to prediction of cellular pro-
teases involved in their development namely Meprin A subunit α and Kallikrein-6. Subsequent
identification of the proteases was verified by immunohistochemistry in normal liver, cirrhosis and
hepatocellular carcinoma. Histopathological assessment of the proteases revealed numerical gradient
staining signifying their involvement in liver fibrosis and hepatocellular carcinoma formation. The
discovered urinary peptides offered a potential noninvasive tool for diagnosis and prognosis of
hepatocellular carcinoma.
Abstract: Hepatocellular carcinoma (HCC) is known to be associated with protein alterations and
extracellular fibrous deposition. We investigated the urinary proteomic profiles of HCC patients in
this prospective cross sectional multicentre study. 195 patients were recruited from the UK (Coventry)
and Germany (Hannover) between 1 January 2013 and 30 June 2019. Out of these, 57 were HCC
patients with a background of liver cirrhosis (LC) and 138 were non-HCC controls; 72 patients
with LC, 57 with non-cirrhotic liver disease and 9 with normal liver function. Analysis of the
urine samples was performed by capillary electrophoresis (CE) coupled to mass spectrometry (MS).
Peptide sequences were obtained and 31 specific peptide markers for HCC were identified and
further integrated into a multivariate classification model. The peptide model demonstrated 79.5%
sensitivity and 85.1% specificity (95% CI: 0.81–0.93, p < 0.0001) for HCC and 4.1-fold increased risk of
death (95% CI: 1.7–9.8, p = 0.0005). Proteases potentially involved in HCC progression were mapped
to the N- and C-terminal sequence motifs of the CE-MS peptide markers. In silico protease prediction
revealed that kallikrein-6 (KLK6) elicits increased activity, whilst Meprin A subunit α (MEP1A) has
reduced activity in HCC compared to the controls. Tissue expression of KLK6 and MEP1A was
subsequently verified by immunohistochemistry.
Keywords: hepatocellular carcinoma; capillary electrophoresis mass spectrometry; urinary peptides;
diagnosis; prognosis
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1. Introduction
Hepatocellular carcinoma (HCC) incidence is increasing worldwide, and it is the third
most frequent cause of cancer related death globally [1]. HCC is more frequent in males
than females and usually occurs at older ages (>60 years). Most patients who develop
HCC are asymptomatic in the early stages of disease, with features of abdominal pain,
abdominal mass and deranged liver function tests (LFTs) infrequently present. HCC is
typically identified clinically when patients affected by liver cirrhosis (LC) develop sudden
hepatic decompensation with features such as ascites, jaundice, hepatic encephalopathy, or
variceal bleeding [2–4].
HCC is the end result of progressive liver fibrosis and liver cirrhosis (LC). Various
causes can lead to chronic liver injury provoking an inflammatory response and resulting
in liver fibrosis through activation of the hepatic stellate cells. At the molecular level, this
activation is associated with protein changes in the liver extracellular matrix (ECM). The
ECM consists of an array of various proteins that comprise the scaffolding of the liver.
Morphologically liver fibrosis is characterized by an excessive deposition of collagen-rich
ECM components [5].
For many years, 2D gel electrophoresis was the principal proteomic technology. It is
now largely replaced by mass spectrometry detection usually connected to a preceding non-
gel-based separation through liquid chromatography (LC) or capillary electrophoresis (CE)
enabling multidimensional analyte detection in complex biofluids with high-resolution
capacity. Due to these characteristics, mass spectrometry-based techniques are increasingly
used in medical research including proteomic characterization, biomarker identification
and diagnostic evaluation of liver and other tumours [6–9]. Capillary electrophoresis mass
spectrometry (CE-MS) has emerged in recent years as a hybrid technology using capillary
electrophoresis (CE) instead of liquid chromatography for sensitive (up to 1 fmol) and high-
resolution low molecular weight protein and peptide separation before mass spectrometry
(MS). CE-MS does not require a sieving matrix, and it also does not depend on buffer
gradients and, since no continuous adaptation of electrospray conditions is needed for
optimal ionization, separation and detection of samples can be conducted fully automated.
Clinical application of the CE-MS system used in this study has been demonstrated in
technical reports and previous large-scale clinical studies [10–13]. Notably, this method
enables profiling of the proteomic content of body fluids, such as urine, plasma or bile, in a
mass range of 0.8 to 20 kilodalton (kDa). So far, it is one of the most applicable methods
for monitoring of systemic catabolic processes caused by differences in the proteolytical
environment at tissue and organ sites [14–16].
In this multicentre study, we applied the CE-MS technology to investigate the low
molecular weight proteome of urine from patients with HCC and non-HCC but with
various liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic
steatohepatitis (NASH) and liver cirrhosis (LC). The purpose of this study was to identify
peptide markers specific for HCC, as currently there are none suitable in clinical practice.
Urine as a biological medium is easy to collect and will be better accepted as an investigative
tool for HCC.
Considering the latest advancements in machine learning, the aim was to integrate
the markers in a multivariate classification model. Apart from combining these peptide
markers to a multivariate pattern to support HCC diagnosis, we additionally investigated
the origin of these peptide fragments by resolving their amino acid sequence and by
searching for proteases involved in their generation through the in silico mapping software
tool Proteasix [17]. This tool enables the linking of peptide fragments to active proteases
and is therefore the bridge between the phenotype depicted in the low molecular weight
proteome (consisting of naturally occurring peptides as a result of proteolysis) and the
protease activity as a result of molecular pathophysiological mechanisms that are altered
in diseases. This online open-source tool uses an input peptide list and allows for auto-
matic cleavage site reconstruction and protease associations based on N- and C- terminus
mapping. In this study, in silico prediction of potential proteases was performed as proof
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for their involvement in peptide cleavage that occurs in HCC pathogenesis at the tumour
site. The mapped proteases were additionally evaluated for differences in their proteomic
expression by immunohistochemistry (IHC) in liver tissues of patients with HCC, LC or
normal liver.
2. Materials and Methods
2.1. Ethics
In the UK, the study was approved by both the Coventry and Warwickshire and the
Northeast York Research National Health Service Ethics Committees (Reference numbers
09/H1211/38 and 19/NE/0213). To access stored tissue samples for the purpose of im-
munohistochemistry, we were granted an ethical approval from the Arden Tissue Bank, UK
(Reference No. ATB19-013). In Germany, the study was approved by the Ethics Committee
of the Medical School Hannover (Reference number: 901). The study conformed to the
World Medical Association Declaration of Helsinki, with all study participants providing
written informed consent.
2.2. Study Design
This was a prospective cross-sectional study that included a discovery phase and a
validation phase. Participants in the study were recruited between 1 January 2013 and
30 June 2019 at both University Hospital Coventry and Warwickshire, UK and Hannover
Medical School, Germany. A follow-up period to note death outcomes was closed on
15 November 2020. In the discovery phase, we prospectively recruited 18 HCC cases and
51 non-HCC cases, while, in the validation phase, we prospectively recruited 39 HCC and
87 non-HCC cases. Diagnosis of these patients was established by a combination of liver
ultrasound, laboratory markers, Fibrosis 4 index (FIB-4), CT/MRI scans, and histology. The
HCC diagnosis was in line with international diagnostic criteria used in Europe [3]. HCC
patients were recruited before receiving anti-cancer treatment. Clinical characteristics of
recruited patients are demonstrated in Table 1. Graphical abstract and schematic flow chart
showing the different phases of the study are shown in Supplementary Figures S1 and S2.
2.3. Sample Preparation
Five mL of urine was collected from all study participants in standard universal speci-
men containers (Newport, UK) and was frozen to −80 ◦C, after collection, for subsequent
batch analysis. For proteomic analysis, the urine samples were prepared as previously de-
scribed [18]. In brief, a 0.7 mL aliquot was thawed immediately before use and diluted with
0.7 mL 2 M urea, 10 mM NH4OH containing 0.02% Sodium Dodecyl Sulphate. To remove
proteins of higher molecular mass (e.g., albumin and immunoglobulin G), the sample was
filtered using a Centrisart ultracentrifugation filter device (20 kDa molecular weight cut-off;
Sartorius, Göttingen, Germany) at 3000 rcf until 1.1 mL filtrate was obtained. Subsequently,
the filtrate was loaded onto a PD-10 desalting column (GE Healthcare, München, Germany),
and equilibrated in 0.01% NH4OH in HPLC-grade H2O (Roth, Karlsruhe, Germany) in
order to decrease matrix effects by removing urea, electrolytes, and salts, and also to enrich
polypeptides. Finally, all samples were lyophilized, stored at 4 ◦C, and resuspended in
HPLC-grade H2O shortly before CE-MS analysis.
2.4. CE-MS Analysis
CE-MS analysis was performed using a P/ACE MDQ capillary electrophoresis system
(Beckman Coulter, Fullerton, CA, USA) online coupled to a Micro Time-of-Flight MS
(Bruker Daltonic, Bremen, Germany) as described [19]. For CE-MS coupling, the ESI sprayer
(Agilent Technologies, Palo Alto, CA, USA) was grounded, ion spray interface potential set
between −4.0 and −4.5 kV and MS acquisition methods automatically controlled by the
CE via contact-close-relays. Spectra were accumulated every 3 s over a range of m/z 350 to
3000. Details on accuracy, precision, selectivity, sensitivity, stability, and reproducibility of
the CE-MS method have been established [20].
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Table 1. Clinical and demographic data of HCC case and non-HCC control patients included in the discovery and validation phase of the study. Parameters, demonstrating significant
differences between the HCC and non-HCC groups, were further investigated using one-way ANOVA on subgroups of patients with NAFLD (n = 27), NASH without LC (n = 14), LC
(n = 72) and HCC (n = 57). The respective Box-and-Whisker distribution plots are presented in Supplementary Figure S3.
Study Phase Discovery Validation
Patient Group HCC Non-HCC p * HCC Non-HCC p *
Patients/samples, n 18/18 51/51 n.a. 39/39 87/87 n.a.
Age, years, mean/range 58/28–76 52/18–82 0.08 67/38–87 56/20–85 0.0001
Female/male, n 3/15 20/31 0.14 9/30 35/52 0.07
No. detected peptides, mean/range 1753/623–2965 2329/920–4488 0.02 2872/1073–4617 2461/811–4057 0.008
Liver cirrhosis, n (%) 18 (100) 25 (49) <0.0001 28 (72) 47 (54) 0.08
Diabetes mellitus, n (%) 3 (17) 13 (25) 0.53 16 (41) 23 (26) 0.14
Body mass index, mean/range 26.8/18.3–32.1 27.8/20.3–41.7 0.76 27.7/20.2–41.0 27.5/16.4–46.6 0.52
Platelet count, ×109/L, mean/range 99/26–310 162/25–391 0.02 195/28–595 234/44–961 0.04
a-Fetoprotein (AFP), µg/L, mean/range 1821/3–22,826 4/1–50 <0.0001 6669/1–107,202 39/1–1493 <0.0001
Alkaline phosphatase, U/L, mean/range 151/60–380 125/45–797 0.008 291/83–1781 196/37–693 0.02
Aspartate aminotransferase (AST), U/L, mean/range 74/24–284 49/13–120 0.03 112/26–457 69/13–1606 <0.0001
Alanine aminotransferase (ALT), U/L, mean/range 61/14–288 53/10–304 0.84 69/12–242 72/7–1038 0.37
AST:ALT ratio, mean/range 1.48/0.89–3.41 1.17/0.20–3.20 0.05 2.11/0.55–7.46 1.13/0.18–3.06 0.0004
Approx. Ishak Fibrosis Score as per FIB-4 index, n, 0–1/2–3/4–6 0/1/17 14/12/17 0.0004 2/9/28 36/28/23 <0.0001
Albumin, g/L, mean/range 32/19–48 40/26–51 0.0003 34/16–48 38/15–70 0.01
Bilirubin, µmol/L, mean/range 27/9–86 26/3–163 0.05 43/6–254 34/3–390 0.03
ALBI stage, n, 1/2/3 2/11/5 26/15/4 0.003 11/20/8 47/22/18 0.009
Liver Disease Etiology, n
Primary HCC 0 0 1 0
Alcoholic cirrhosis (C2) 7 4 7 6
Virus-related cirrhosis (HBV/HCV/HDV) 3/4/0 0/4/1 3/4/0 2/2/0
Cryptogenic/Biliary cirrhosis 0/0 3/1 1/0 2/0
Hereditary (Mucoviscidosis/Hemochromatosis/AATD) 1/1/0 0/0/0 1/0/1 0/0/0
Cholestasis (PBC/PSC/SSC/PFIC) 2/0/0/0 2/2/1/1 2/5/0/0 2/14/1/0
Autoimmune hepatitis (AIH) 0 2 0 0
NAFLD/NASH/NASH-LC 0/0/0 9/8/4 0/2/12 18/6/15
GI cancer (CCA/PCA) with LC 0/0 0/0 0/0 7/2
Other benign liver diseases (CHP/CDL) 0/0 0/0 0/0 7/3
No liver disease 0 9 0 0
* Mann–Whitney U test for continuous data and significance level by Fisher’s exact or chi-squared test for categorical data. Abbreviations: AATD, a-1 antitrypsin deficiency; CCA, cholangiocarcinoma; CDL,
choledocholithiasis; CHP, chronic pancreatitis; HCC, hepatocellular carcinoma; LC, liver cirrhosis; NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cholangitis;
PCA, pancreatic cancer; PFIC; progressive familial intrahepatic cholestasis; PSC, primary sclerosing cholangitis; SSC, secondary sclerosing cholangitis.
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2.5. CE-MS Data Processing
Mass spectral ion peaks, representing identical peptides at different charge states, were
deconvoluted into single masses using MosaiquesVisu software [21]. For noise filtering, sig-
nals with z > 1 observed in a minimum of 3 consecutive spectra with a signal-to-noise ratio
of at least 4 were considered. MosaiquesVisu employs a probabilistic clustering algorithm
and uses both isotopic distribution (for z ≤ 6) and conjugated masses for charge-state de-
termination of peptides/proteins. The resulting peak list characterizes each peptide by its
mass and its migration time. Time-of-flight-MS data were calibrated utilizing 150 reference
mass data points and 452 reference migration time data points by applying global and local
linear regression, respectively. Ion signal intensity (amplitude) varied between samples,
mostly due to different amounts of salt and peptides in the sample and were therefore
normalized. Reference signals of 29 highly abundant peptides were used as “internal stan-
dard” peptides for calibration using local linear regression [22]. This procedure was shown
to be an easy and reliable method to address both analytical and dilution variances in a
single calibration step. The obtained peak list characterizes each peptide by its calibrated
molecular mass [Da], calibrated CE migration time [min], and normalized signal intensity.
All detected peptides were deposited, matched, and annotated in a Microsoft SQL database
allowing further statistical analysis. The raw data files are uploaded to the open access
database Zenodo; https://zenodo.org/ and are linked to the DOI: 10.5281/zenodo.5138595
last accessed on 21 July 2021.
2.6. Support Vector Machine Model Generation and Classification
For the integration of a set of peptides to a support vector machine (SVM) classifica-
tion model, the MosaCluster v.1.7.5 software was applied (Biomosaiques Software GmbH,
Hannover, Germany). MosaCluster constructs a high-dimensional parameter space based
on the amplitudes of the selected peptides and defines a separation hyperplane between
two groups defined as case or control during the supervised learning phase. After estab-
lishment, such an SVM peptide marker model can be used for diagnosis by assigning to
each patient’s CE-MS profile a membership value according to the level of similarity to
either the case or control group used for training. To compensate for imbalanced data,
MosaCluster includes a class-weighting function based on the ratio of the two classes,
which is used for assigning higher misclassification penalties to the larger group.
2.7. Peptide Sequencing
Peptide sequencing was carried out both on a Dionex Ultimate 3000 RSLS nanoflow
system (Dionex, Camberley, UK) and a Beckman CE/Orbitrap Q Exactive plus combination
(Thermo Scientific, Waltham, MA, USA) [23]. Spectra files were analyzed with Proteome
Discoverer 2.4 (Thermo Scientific) allowing a precursor mass tolerance of 5 ppm and a
fragment mass tolerance of 0.05 Da. This was followed by a search using the SEQUEST
search engine against the UniProt human non-redundant database (https://www.uniprot.
org/, last accessed on 9 March 2021) without any protease specificity or fixed modification.
Oxidation of methionine and proline were considered as variable modifications. Only
sequences with high confidence (Xcorr ≥ 1.9) and without unmodified cysteine (due to the
application of non-reducing conditions) were accepted [24]. A strong correlation between
peptide charge at the CE operating pH of 2 deduced from the number of basic amino acids
in the annotated peptide sequence and the migration time was used as another criterion to
prevent false sequence assignments [25].
2.8. In Silico Protease Prediction
In silico protease assessment was performed using Proteasix (www.proteasix.org, last
accessed on 18 March 2021), the web-based tool for investigation of proteolytic events
involved in naturally occurring peptide generation [17]. Observed specific proteases
responsible for cleavage of N- or C- terminus of a peptide were retrieved from CutDB
proteolytic event database available at www.cutdb.burnham.org (last accessed on 18 March
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2021) [26]. Protease activity was assessed in the patient’s CE-MS peptide profiles to gain
fold-changes between HCC cases (n = 18) versus the controls with other cirrhotic and
non-cirrhotic liver diseases (n = 51) based on the average of associated peptide intensities.
This method is described in detail by Voigtländer et al. [15].
2.9. Immunohistochemistry
To further evaluate the presence of kallikrein-6 (KLK6) and meprin A subunit α
(MEP1A), as the two proteases with the highest activity score according to Proteasix, the
Arden tissue bank provided us with liver tissue sections. We extracted 14 cases (5 with
HCC, 4 with benign liver disease including cirrhosis and 5 cases with normal liver tissue
without disease). For both KLK6 and MEP1A detection, we used commercial polyclonal
goat IgG antibodies known to react to human tissue (R&D Systems, Abingdon, UK). We
first optimized the antibodies; the human protein atlas was queried, to investigate the
current guidance on antibody dilutions and anticipated staining patterns for both KLK6 and
MEP1A. Following optimization on test cases, we used a KLK6-specific primary antibody
at a dilution of 1:200 and MEP1A-specific primary antibody at a dilution of 1:1400 for all
immunohistochemistry. Each tissue section was reviewed by a Gastrointestinal Pathologist
to ensure that adequate tissues were present prior to staining. For immunohistochemistry
assessment of the detected protease, the Allred Scoring system for stain intensity was used;
0 for Negative (no staining of any nuclei at high magnification), 1 for weak (only visible at
high magnification), 2 for Moderate (readily visible at low magnification), and 3 for strong
(strikingly positive at low magnification) [27]. Detailed steps for immunohistochemistry
are described in the supplementary material.
2.10. Statistics
p-values for group-specific differences in peptide distributions were calculated based
on natural logarithmic transformed ion signal intensities and the Wilcoxon rank sum
test using the statistical programming language R. Statistical adjustment of p-values due
to multiple testing was performed by the Benjamini and Hochberg method [28]. All
other statistical analyses were carried out using the statistical software MedCalc version
12.7.5.0 (MedCalc Software; Mariakerke, Belgium). Receiver operating characteristics (ROC)
analysis was used to determine estimates of sensitivity and specificity for classification
also including exact binomial calculations for confidence intervals. ROC analysis and
the determination of AUC values thereof were used as these are accepted descriptors
to determine diagnostic test accuracy. A major characteristic of ROC analysis is that it
describes the classifier’s performance over the entire range of criterion values and therefore
provides the advantage to be independent of any particular threshold. The relationship
between proteomic classification to demographic variables was performed by binomial
logistic regression analysis. Overall survival was analyzed by Kaplan–Meier methodology
and a log-rank test to compare patients with a positive test result versus those with a
negative test result by the HCC proteomic test.
3. Results
3.1. Identification of Urinary Peptides as HCC Progression Markers by CE-MS Analysis
The urine samples of the HCC study cohort were analysed by CE-MS resulting in
a list of 7259 peptides in the molecular mass range between 800 and 20,000 Dalton and
with a frequency of occurrence in at least 20% of samples. A threshold of 20% was chosen
to have on the one side a sufficient high parameter space and on the other side can still
handle the zero-inflated data matrix of peptide signal amplitudes in the CE-MS peptide
profiles. The latter criterion is of particular relevance for differential analysis of single
peptide distributions.
In order to identify urinary peptides with differential regulation between HCC case
and normal or liver fibrotic control groups, we followed a two-step selection approach.
Firstly, we performed a group-wise comparison of 18 urine samples from HCC patients
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and 51 non-HCC controls (25 LC, 8 NASH w/o LC, 9 NAFLD, 9 center-matched healthy
individuals) by a parametric Wilcoxon rank sum test. This resulted in the identification
of 123 peptides with a p-value below 0.05 after false discovery rate (FDR) adjustment
by the method of Benjamini and Hochberg [28]. Using this extended set of markers, we
subsequently performed a search for those peptide markers that showed a gradual increase
or decrease in their CE-MS-detected amplitude signals from normal or non-cirrhotic liver
disease including NAFLD and NASH without cirrhosis over LC of different aetiology to
HCC (for details on patient characteristics see Table 1). This selection procedure resulted
in a list of 31 out of the set of 123 peptides with significant Spearman Rho correlation
coefficients after FDR adjustment either above 0.3 or below −0.3 defining a source of HCC
progression markers. The 31 peptides with significant association to HCC including all
their statistical characteristics are presented in Table 2.
3.2. Development of the 31 HCC Progression Markers to a Multivariate Classification Model
The 31 selected peptides were combined to a support vector machine (SVM)-based
peptide model. This SVM model, named HCC-31, was trained during the supervised
learning phase using the 18 HCC and 51 non-HCC control patients of the discovery
study cohort to differentiate between HCC and non-HCC specific peptide marker patterns.
Concerning SVM characteristics, HCC-31 is based on a radial basis function (RBF) kernel of
C-SVC type with C = 2.2691, g = 0.0764 and eps = 0.001 as fixed kernel parameter settings.
Selection of an RBF kernel of C-SVC was found to be the best option for data matrices with
frequent occurrence of zero intensity values as represented by CE-MS peptide profiles [29].
After optimization of the SVM parameters and total cross-validation on the original training
data, the peptide marker pattern resulted in an AUC of 0.92 (95% confidence interval (CI):
0.87 to 0.96, p < 0.0001) in receiver operating characteristics analysis (ROC). The optimal
threshold for an HCC positive test result was determined based on the Youden index to be
−0.25 resulting in a sensitivity of 86.8% (95% CI: 74.7–94.5) and a specificity of 89.0% (95%
CI: 81.2–94.4).
In order to determine the model’s accuracy without overfitting bias, the HCC-31
model was subsequently tested on an independent cross-sectional cohort of patients of
whom 39 had a clinical diagnosis for HCC and 87 for other liver diseases. As presented in
Figure 1, independent validation of the HCC-31 model resulted in an AUC of 0.88 (95%
CI: 0.81–0.93, p < 0.0001), and 79.5% sensitivity and 85.1% specificity at the predetermined
threshold at −0.25. When classification by the HCC-31 model was adjusted for age and
gender of the patients in the validation cohort, the AUC in ROC analysis was significantly
increased from 0.88 to 0.94 (p = 0.008). Based on the age- and gender-matched HCC-31
model, only two out of the 39 HCC cases were missed, as they were classified as controls
(false negatives).
Subsequently, we investigated the prognostic value of a positive HCC-31 test, by
investigating whether the classification result is a significant predictor of overall mortality
during a follow-up period of 500 days starting from the date of sample collection. As
revealed by the Kaplan–Meier survival curves in Figure 2, patients with a positive HCC-31
test had a 4.1-fold increased risk of death (95% CI: 1.7–9.8, p = 0.0005) compared to patients
with a negative test during the 500-days follow-up.
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8720 6.37 × 10−04 0.75 −0.587 8.05 × 10−06 658 (664) 73 231 (641) 48 31 (98) 11
9080 3.34 × 10−02 0.65 0.391 5.69 × 10−03 813 (2125) 15 893 (1236) 48 1618 (1815) 61
9510 5.03 × 10−03 0.72 0.370 9.56 × 10−03 2227 (4587) 31 2847 (4477) 68 4563 (3380) 83
9728 1.90 × 10−03 0.73 0.511 1.51 × 10−04 345 (745) 23 902 (1038) 56 1359 (916) 89
10177 3.24 × 10−03 0.71 0.358 1.29 × 10−02 162 (288) 38 170 (224) 48 476 (376) 89
11725 6.63 × 10−04 0.65 0.385 6.64 × 10−03 0 (0) 0 4 (12) 8 28 (50) 33
12459 8.13 × 10−06 0.86 −0.526 8.68 × 10−05 373 (152) 96 335 (236) 92 119 (124) 61
13134 7.85 × 10−04 0.73 0.311 3.45 × 10−02 32 (73) 27 170 (375) 24 364 (411) 67
13176 1.20 × 10−03 0.73 0.410 3.47 × 10−03 27 (54) 27 103 (190) 40 171 (155) 72
14389 5.32 × 10−04 0.74 −0.400 4.53 × 10−03 53 (64) 54 20 (37) 40 0 (0) 0
14925 7.69 × 10−04 0.73 −0.567 1.82 × 10−05 689 (1120) 58 237 (627) 32 0 (0) 0
15342 1.38 × 10−04 0.80 −0.604 3.66 × 10−06 766 (308) 100 420 (323) 76 224 (219) 78
17066 1.33 × 10−04 0.66 0.397 4.89 × 10−03 0 (3) 4 8 (53) 4 257 (693) 33
17805 8.75 × 10−04 0.75 −0.514 1.37 × 10−04 394 (478) 69 235 (349) 52 16 (36) 22
19681 5.57 × 10−04 0.76 −0.630 1.14 × 10−06 127 (129) 85 34 (53) 40 9 (21) 17
20237 1.82 × 10−04 0.79 0.483 3.69 × 10−04 292 (480) 35 316 (635) 56 940 (1064) 94
24328 2.07 × 10−05 0.84 −0.636 8.84 × 10−07 5557 (3207) 100 2341 (2674) 100 890 (1187) 72
29919 1.20 × 10−02 0.69 0.465 6.63 × 10−04 199 (505) 23 525 (661) 60 857 (1223) 78
† Peptide identification number. § acc. non-paramteric Wilcoxon signed rank sum test. # non-LC group with normal controls (n = 9), NAFLD (n = 9) and NASH w/o LC (n = 8). ‡ Correction for multiple testing by
the method of Benjamini and Hochberg. Abbreviations: AUC, area under curve; Freq, frequency of occurrence (%); HCC, hepatocellular carcinoma; LC, liver cirrhosis; Mean Amp, mean signal amplitude (ion
counts); n, number of patients; NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; SD, standard deviation.
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3.3. CE-MS and Peptide Sequence Characteristics of the Peptide Marker Candidates
For the 31 peptides that were identified as differentially excreted in the urine between
HCC cases and disease matched controls, amino acid sequences were assigned based on
mapping of the CE-MS characteristics (CE migration time and MS-detected molecular
mass) to the urinary peptide sequence database [30]. The CE-MS characteristics for the
31 peptides together and the sequence information for all sequence identified peptides
(n = 27) are presented in Table 3.
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Table 3. Characterization of the 31 urinary HCC peptide markers by amino acid sequencing and in silico protease prediction analysis together with their experimental spectrometry mass,















54 807.39 23.2 CLU 366–371 — LNEQ|FNWVSR|LANL —
1059 920.34 21.2 — — — — —
1160 928.51 24.6 UMOD 592–599 MEP1A, MMP3 RSGS|VIDQSRVL|NLGP MEP1A, KLK6, CTS [B,D,E]
1778 981.49 24.4 ACTB 107–115 MEP1A, MMP [3,13], CTS [B,D,E] HPVL|LTEAPLNPK|ANRE —
2314 1032.45 25.9 ACTB 95–103 — YNEL|RVAPEEHPV|LLTE MEP1A, MMP [3,13], CTS [B,D,E]
3559 1134.59 24.0 COL3A1 755–766 — ADGV|PGKDGPRGPTGP|IGPP —
3662 1142.55 22.0 ADGRF3 56–64 — DKAW|NERIDRPFP|ACPI —
4564 1199.55 20.8 TKT 343–352 — DGDT|KNSTFSEIFK|KEHP —
4610 1201.53 24.9 GAGE12H 58–70 MEP1A, MMP3, CTSB AAAQ|KGEDEGASAGQGP|KPEA MMP3
4829 1217.48 27.7 COL3A1 179–191 — PAGP|pGPpGPpGTSGHp|GSPG KLK6, CTSB
5284 1250.64 20.6 HBB 136–147 — QKVV|AGVANALAHKYH C-terminal end
6601 1352.78 22.0 AHNAK 772–784 — EVDV|NLPKADVDISGPK|IDVT MEP1A, KLK6
6607 1353.53 23.8 FGA 605–617 MEP1A YKMA|DEAGSEADHEGTH|STKR —
8720 1513.62 29.5 CDH1 397–410 — ITTL|KVTDADAPNTPAWE|AVYT —
9080 1539.74 40.4 COL18A1 1400–1416 MEP1A, CTSB EGRQ|GPpGPpGPPGPPSFPGP|HRQT MMP3
9510 1576.68 44.9 — — — — —
9728 1594.77 40.3 COL1A1 1177–1194 MMP3 DAGP|VGPpGPpGPpGPpGPPSA|GFDF MMP [3,13], CTSB
10177 1624.73 25.1 COL2A1 1150–1167 — GPSG|DQGASGpAGpSGpRGPpG|PVGP —
11725 1733.73 29.8 GSN 605–621 CTSD AAYL|WVGTGASEAEKTGAQEL|LRVL MEP1A, MMP3, CTS [D,E]
12459 1782.85 26.0 — — — — —
13134 1836.79 31.1 COL1A2 918–937 MMP3 SPGV|NGApGEAGRDGNPGNDGPpG|RDGQ MEP1A, MMP [3,13], CTSB
13176 1840.83 41.9 COL2A1 1193–1213 MEP1A, KLK6 PRGR|SGETGPAGppGNPGPPGPpGP|PGPG KLK6
14389 1930.89 31.6 COL3A1 618–639 MEP1A, CTSB TGPQ|GPpGPTGPGGDKGDTGPpGPQG|LQGL MEP1A, MMP [3,13], CTSB
14925 1972.96 25.0 PCSK1N 223–241 MEP1A RRAA|DHDVGSELPPEGVLGALLR|VKRL MEP1A, MMP [3,13]
15342 2009.88 32.4 COL5A2 136–157 MEP1A, MMP [3,13], CTSB GAPG|SKGEAGpTGPMGDpGTVGPPGP|VGER MMP3
17066 2169.98 33.7 COL16A1 1145–1166 MEP1A, MMP [3,13], CTSB GPQG|NSGEKGDQGFQGQPGFpGPPGP|PGFP —
17805 2232.00 33.6 COL5A1 999–1021 — PPGV|VGpQGpTGETGpMGERGHPGPpG|PPGE MEP1A, CTSB
19681 2380.08 35.8 COL3A1 201–228 MEP1A, CTSB PGYQ|GPPGEPGQAGpSGpPGppGAIGPSGPAG|KDGE MEP1A, MMP [3,13], CTSB
20237 2430.60 35.7 — — — — —
24328 2854.37 34.6 COL3A1 616–646 CTSB GETG|PQGPpGPTGpGGDKGDTGPpGPQGLQGLpGT|GGPP MEP1A, CTSB
29919 3524.75 32.4 CLU 390–423 — VTTV|ASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEV|SRKN MMP3
ACTB, Actin, cytoplasmic 1; ADGRF3, Adhesion G-protein coupled receptor F3; AHNAK, Neuroblast differentiation-associated protein; CDH1, Cadherin-1; CLU, Clusterin; COL1A1, Collagen α-1(I) chain; COL1A2,
Collagen α-2(I) chain; COL2A1, Collagen α-1(II) chain; COL3A1, Collagen α-1(III) chain; COL5A1, Collagen α-1(V) chain COL5A2, Collagen α-2(V) chain; COL16A1, Collagen α-1(XVI) chain; COL18A1, Collagen
α-1(XVIII) chain; CTS, Cathepsin; FGA, Fibrinogen α chain; GAGE12H, G antigen 12H; GSN, Gelsolin; HBB, Hemoglobin subunit β; KLK6, Kallikrein-6; MEP1A, Meprin A subunit α; MMP, Matrix metallopeptidase;
PCSK1N, ProSAAS; TKT, Transketolase; UMOD, uromodulin.
Abbreviation: AA, amino acid sequence; CE, capillary electrophoresis; Exp. mass, experimental mass. † Peptide identification number. ‡ Lower case p expresses hydroxyproline.
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Following the hypothesis that peptides emerge from proteolytical processing of pro-
teins and that peptides serve as substrates of disease-specific changes to the proteolytic
environment, in silico mapping was performed on the 27 sequence identified HCC peptide
marker of the HCC-31 model. In total, 18 protease candidates were found to be associated
with the sequence motifs at the N- and C-terminal ends of the 27 peptides. Out of these,
seven showed significant differences in the ion signal intensities of their mapped peptide
substrates between the HCC case and other liver disease control groups after adjustment
for multiple testing. As presented in Table 4, kallikrein-6 (KLK6), the matrix metallopepti-
dase (MMP) 3 and 13 and the cathepsins (CTS) D and E were predicted to be significantly
increased, whereas meprin A subunit α (MEP1A) and CTSB were found to be decreased in
their activities in HCC compared to non-HCC liver diseases (p < 0.05 in the Mann–Whitney
U test).
Table 4. Differences in the activities of the seven in silico predicted proteases meprin A subunit α
(MEP1A), matrix metallopeptidase (MMP) 3 and 13, kallikrein-6 (KLK6) and cathepsin (CTS) B, D
and E based on the fold change of the protease associated peptide substrate’s ion signals between the








Group (n = 18)
Non-HCC Liver Disease
Control Group (n = 51)
MEP1A 196.23 ± 93.19 365.65 ± 231.12 0.54 0.003
MMP3 632.99 ± 317.56 393.63 ± 331.29 1.60 0.007
MMP13 729.36 ± 402.76 495.03 ± 539.78 1.47 0.012
KLK6 166.40 ± 79.87 67.09 ± 88.51 2.47 <0.0001
CTSB 347.63 ± 173.67 643.77 ± 399.10 0.53 0.004
CTSD 32.90 ± 33.44 17.35 ± 31.21 1.89 0.015
CTSE 34.41 ± 31.99 22.56 ± 41.25 1.52 0.031
3.4. Differential Expression of KLK6 and MEP1A in HCC, Cirrhosis and Normal Liver Tissue
The proteases KLK6 and MEP1A were selected for immunohistochemical (IHC) stain-
ing of liver biopsy sections since they showed the highest difference in activity between
HCC cases and controls in Table 4. For the investigation of KLK6 and MEP1A tissue ex-
pression, liver biopsy sections from five HCC, four benign liver disease including cirrhosis
and five cases with normal liver tissue without disease were selected from the Arden tissue
bank. As shown in Figures 3–5, incremental gradient staining ranging from mild staining
in normal liver tissue, to moderate staining in liver cirrhosis and then to strong diffuse
staining in HCC was observed for KLK6. For MEP1A, there was an absence of staining
in cirrhosis and HCC, whereas it was mildly present in normal liver tissue (Figures 6–8).
The IHC suggests that KLK6 increase with cirrhosis and HCC while MEP1A decrease
in cirrhosis and HCC. For gradient staining, we used the Allred score [27], and this is
demonstrated in all tested histopathological sections in Table 5.
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Figure 3. IHC characteristics of kallikrein-6 (KLK6) in HCC at low power magnification (X10). The brown chromogen 
indicated protein expression of KLK6 in the nucleus and cytoplasm of the hepatic and stromal cells. Slide shows infiltrating 
nests and cords of atypical hepatocytes in the stroma with mildly pleomorphic nuclei in keeping with moderately differ-
entiated hepatocellular carcinoma, demonstrating high intensity of nuclear and cytoplasmic staining for KLK 6 (Allred 
score 3). 
 
Figure 4. IHC characteristics of kallikrein-6 (KLK6) in liver cirrhosis at low power magnification (X10). The brown chro-
mogen indicated protein expression of KLK6 in the nucleus and cytoplasm of the hepatic and stromal cells. The slide 
shows a section of a cirrhotic liver showing well defined nodules of regenerating hepatocytes with expanded fibrotic portal 
tracts without marked nuclear atypia—demonstrating moderate intensity of nuclear and cytoplasmic staining for KLK 6 
(Allred score 2). 
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(Allred score 2).
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Figure 5. IHC characteristics of kallikrein-6 (KLK6) in normal liver at low power magnification (X10). The brown chromo-
gen indicated protein expression of KLK6 in the nucleus and cytoplasm of the hepatic and stromal cells. The slide shows 
a section of a normal liver containing normal appearing portal tracts and hepatocytes—demonstrating mild intensity of 
nuclear and cytoplasmic staining for KLK6 (Allred score 1). 
 
Figure 6. IHC characteristics of meprin A subunit a (MEP1A) in HCC at low power magnification (X10). The brown chro-
mogen should indicate protein expression of MEP1A in the nucleus and cytoplasm of the hepatic and stromal cells. The 
slide section shows compact sheets and nests with thickened hepatocyte plates with mild cytological atypia in keeping 
with well differentiated hepatocellular carcinoma; staining for MEP1A here was negative (Allred score 0). 
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Figure 7. IHC characteristics of meprin A subunit a (MEP1A) in liver cirrhosis at low power magnification (X10). The 
brown chromogen should indicate protein expression of MEP1A in the nucleus and cytoplasm of the hepatic and stromal 
cells. The slide section of cirrhotic liver shows vague nodule formation with bridging fibrosis; staining for MEP1A here 
was negative (Allred score 0). 
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a normal liver contains normal appearing portal tract and hepatocytes—demonstrating mild intensity of nuclear and cy-
toplasmic staining for MEP1A (Allred score 1). 
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HCC 1 3 0
HCC 2 3 1
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Cirrhosis 4 3 0
Normal liver 1 1 1
Normal liver 2 1 0
Normal liver 3 1 1
Normal liver 4 1 1
Normal liver 5 1 1
4. Discussion
There are no accurate diagnostic biomarkers for HCC or population-based screening.
Additionally, surveillance strategies for HCC are ineffective, relying on liver ultrasound
scans (USS) for the detection of nodules in LC patients, which is dependent on the quality
of training of the USS operator. The role of a fetoprotein (AFP) in HCC surveillance is also
questionable due its poor sensitivity and is no longer recommended for routine use. HCC
diagnosis relies mainly on the ability of advanced, high-resolution imaging techniques
for the detection of liver lesion early arterial enhancement followed by early washout.
These scans are not easily accessible and can be less accurate in detecting lesions <1–2 cm.
The current modalities used are contrast-enhanced triphasic computed tomography (CT)
and/or contrast-enhanced magnetic resonance imaging (MRI). If the scans are inconclusive,
the diagnosis is then confirmed with a cytological or histopathological evaluation of the
liver lesion from tissue biopsy. Treatment and prognostication of patients with HCC
consider the size and number of tumour nodules and their relation to the portal vein, and
the degree of liver impairment [2–4]. Given these factors, there is a need for non-invasive
methods to identify HCC.
In this respect, the present study was focused on the identification of HCC-specific
peptides in urine to first test their diagnostic utility by integration into a peptide marker
model as previously performed for cholangiocarcinoma [15] and pancreatic cancer [31]
and second to trace back systemic alterations of HCC progression to pathophysiological
processes at the tumor site.
The HCC-31 classifier adds to the current modalities for non- or minimal-invasive
HCC diagnosis. To put this in a clinical perspective, the HCC-31 performed better in
comparison to AFP. HCC-31 showed sensitivity of 79.5% while the quoted literature
showed that AFP usually has low sensitivity for HCC detection between 40–65% [32].
Therefore, potential use of HCC-31 is promising if further validated as substitute to AFP in
aiding HCC diagnosis or as a prognostic marker.
HCC-31 utilizes a molecular pattern of 31 peptides, which are surrogate markers for
differential proteolytic activity at the HCC tumor site in comparison to other cirrhotic and
non-cirrhotic liver diseases. Validation of HCC-31 on an independent cross-sectional cohort
of 39 HCC and 87 highly heterogeneous non-HCC liver disease patients from two clinical
populations, one in England and the other in Germany, resulted in an accuracy of 83.3% of
the pure classification model and 91.3% when the model was adjusted for gender and age.
Moreover, HCC-31 positivity was associated with a 4-fold increased risk of death during a
500-day observational period providing further evidence for its clinical applicability.
The 31-HCC model consists of peptides derived from different protein sources in-
cluding cell-derived and structural proteins. As revealed by a literature review, several
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of the HCC-31 peptide markers were also identified in other human body fluids, like
serum, plasma, cerebrospinal fluid, or as HLA-associated immunopeptides in tissue and
are therefore proven not to be restricted to urine (for details, see Table 6) [33–39].
Some of the proteins from which the peptide markers are derived are already described
in the context of HCC, such as CDH1/E-cadherin [40] and AHNAK [41], but most others
are not. Peptides as disease markers add another level of complexity since their expression
differences might not be caused by differential regulation of their parent protein but changes
in the activity of the proteases leading to their generation. Therefore, the common features
qualifying the 31 peptides as HCC markers are most likely their cleavage by proteases
with changes in activity during the course of HCC and the same route of clearance by
incorporation into exosomes, release into the circulation and final excretion into the urine.
Most of the peptides included in HCC-31 are fragments of collagen chains, which are also
identified as source of peptide markers for other diseases by our group [42,43].
Collagen chains are the main components of the extracellular matrix, and their frag-
ments are predominant in the low molecular weight fraction of the urinary proteome [44].
Various proteases are able to cleave collagen chains, most prominent are matrix metallopro-
teinases and cathepsins [45]. In this respect, we were able to detect more than 600 different
partially overlapping peptides derived from collagen α-1(I) chain in urine (unpublished
data). As already described in other studies by our group [46,47], the composition of colla-
gen peptides in urine is strongly associated with changes in specific protease activities at the
site of disease, particularly in progressing tumours and surrounding microenvironment.
Carcinogenesis exact mechanisms are yet to be identified. However, cancer cells’
metabolism involves extracellular proteolytic degradation. This mainly plays a role in cell
migration, tumour growth and distant spreading in the body [48]. Therefore, investigations
at the protein level (proteomics) are advantageous particularly in the case of in-depth
characterization of cancer progression and invasiveness. CE-MS has demonstrated in
this context a good diagnostic potential of urinary peptide biomarkers even for non-renal
diseases with exosomes as the potential trans-renal carriers. These biomarkers have been
identified in the context of a single type of cancer (e.g., bladder, prostate, pancreatic, renal
cell carcinoma and cholangiocarcinoma) [31,47,49,50]. Our results here have demonstrated
that proteolytically processed peptides in the urine can be used in diagnosis and prognosis
of HCC, and this is actually a promising non-invasive tool for precision medicine in the
future. We have also demonstrated that these urinary peptides are related to proteolytic
activities at the tumour site. We chose to demonstrate the predicted proteases in various
stages of liver tissue ranging from normal to cirrhosis and HCC to identify firstly if these
proteases are present and if their staining differs between normal and disease groups,
namely LC and HCC. KLK6 and MEP1A were shortlisted as per the lowest p-value. The
gradient staining confirmed the predicted activity, showing that KLK6 increases with
cirrhosis and HCC, and MEP1A decreases in cirrhosis and HCC.
KLK6 is a protease that belongs to the kallikrein family of fifteen members located
on chromosome 19. KLK6 was shown to be involved in many cancers’ formation and
progression [51–54]. In the liver, KLK6 was shown to catalyse ubiquitin, an important
cellular regulatory protein involved in protein synthesis. KLK6 also was shown to induce
de novo cirrhosis and was increased in HCC tissues [55]. Additionally, a study designed to
check the activity of KLK6 on ECM peptides in HCC revealed that KLK6 has an upregulated
activity [56].
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Table 6. List of HCC-31 peptide markers that were identified in human tissue or body fluids other than urine.
HCC-31 Peptide Marker ID Amino Acid Sequence Protein Name Protein Symbol Biological Source of Identification(Other than Urine) Reference
11354 107-LTEAPLNPK-115 Actin; α skeletal muscle ACTA1
Cerebellum tissue ‡ Marcu et al. [33]
HCC tumor tissue ‡ Liang-Qing et al. [34]
14071 95-RVAPEEHPV-103 Actin, cytoplasmic 1 ACTB Lung tissue ‡ Marcu et al. [33]
25411 179-PGPPGPPGTSGHP-191 Collagen α-1(III) chain COL3A1 Plasma Zakharova et al. [35]
33901 605-DEAGSEADHEGTH-617 Fibrinogen α chain FGA
Serum Ueda et al. [36]
Plasma Koomen et al. [37]
135817 390-ASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEV-423 Clusterin CLU Cerebrospinal fluid Belogurov et al. [38]
57312 605-WVGTGASEAEKTGAQEL-621 Gelsolin GSN Plasma Modzdiak et al. [39]
‡ identified as a HLA-associated immunopeptide.
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MEP1A is a metalloproteinase that belongs to the metzincin family with the main
function in intracellular transport of proteins [57]. MEP1A has been implicated in kidney,
colorectal and pancreatic cancers [31,58,59]. In HCC, MEP1A was shown to promote cell
proliferation, migration and invasion [60,61]. In the present study, we have shown that
MEP1A related peptides in the urine are present in HCC at decreased levels than in our
cirrhosis and non-cirrhosis control group. However, both the staining in cirrhosis and
HCC tissues were negative but present in normal livers. This was also noted by OuYang
et al. [61] on HCC tissues, where immunohistochemical MEP1A expression levels in the
tumour cell cytoplasm varied widely among different HCC specimens. However, the same
group showed that MEP1A was found to be elevated following analysis of the HCC tissues
using quantitative real-time polymerase chain reaction compared with matched adjacent
nonneoplastic tissues and non-malignant liver disease tissues. Differential regulation in
this respect might occur on the protein level, e.g., by secretion of soluble MEP1A, rather
than forming a membrane-bound complex within the cell or on the cell surface [62]. In
addition, the presence of MEP1A in HCC tissues also demonstrated poor prognosis [61].
The predicted seven proteases in this study could also be potential sites for anti-
protease treatment in HCC. An example was demonstrated in a study by Tran et al. [63].
They showed that injection of metalloproteinases (MMPs) inhibitors to HCC cell lines
resulted in delaying HCC growth without treatment related toxicity. MMP inhibitors
also lead to inhibition of angiogenesis and tumour necrosis. Furthermore, anti-cathepsins
were found to promote cell death in a study completed on HepG2 cell lines [64]. These
anti-proteases could be used through an immunotherapy approach in combination with
conventional chemotherapy and/or nanoparticle based intervention.
CE-MS technology has identified an important sequence of urinary peptides related
to proteolytic activity in HCC. The technology paves the way for future work on these
peptides to develop a noninvasive test that could be applied early for purpose of screening,
surveillance and/or diagnosis. The study was limited by the relatively small number of pa-
tients, small number of human liver tissue samples and its exploratory nature; nonetheless,
it was multicentre and validated across two populations. In addition, the presentation of
the predicted proteases was verified at the tissue level demonstrating that these urinary
peptides are related to the HCC disease formation in the liver.
5. Conclusions
Urinary CE-MS analysis identified proteases specific to HCC. In addition, the specific
HCC peptide model showed good diagnostic performance and prognostic ability in relation
to outcomes.
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